Trailing-twelve-month (TTM) revenue is $16.70 Billion with a year-over-year growth of (4.58%). Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $4,254,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-10-31 |
| Q4 FY2025Period ended 2025-12-31 | $4,422,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-26 |
| Q1 FY2026Period ended 2026-03-31 | $4,068,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-05 |
| Q2 FY2026Period ended 2026-06-30 | $3,961,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-03 |
| TTM revenue | $16,705,000,000 |
Current P/S: $14,703,619,412 market capitalization ÷ $16,705,000,000 TTM revenue = 0.88x.
Market capitalization source: FMP quote. Quote observed 2026-09-25T19:50:19.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $3.96B.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-09-25T19:51:57.592Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-11.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2024-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20232023-12-31 · USD | FY20242024-12-31 · USD |
|---|---|---|
| Insurance | $3.6B | $3.6B |
| Other Operating Segment | N/A | $197M |
| Reinsurance | $9.8B | $11.4B |
$16.70B
$16.70 Billion
(4.58%)
vs. $17.51B a year ago (TTM)
+8.34%
5 Year compound annual growth rate
1 Year
(4.58%)
3 Year
+8.13%
5 Year
+8.34%
10 Year
+11.62%
15 Year
+8.64%
20 Year
+6.89%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $17.32B | +$242.00M | +1.42% |
| 2024 | $17.08B | +$2.61B | +18.06% |
| 2023 | $14.46B | +$2.48B | +20.68% |
| 2022 | $11.98B | +$657.00M | +5.80% |
| 2021 | $11.33B | +$1.73B | +18.02% |
| 2020 |
TTM Growth
(4.58%)
3-Year CAGR
+8.13%
5-Year CAGR
+8.34%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
| $9.60B |
| +$1.37B |
| +16.61% |
| 2019 | $8.23B | +$869.67M | +11.81% |
| 2018 | $7.36B | +$739.20M | +11.16% |
| 2017 | $6.62B | +$827.95M | +14.29% |
| 2016 | $5.79B | +$117.58M | +2.07% |
